美沙拉嗪联合酪酸梭菌活菌治疗溃疡性结肠炎疗效分析  

Clinical efficacy of mesalazine combined with Clostridium butyricum tablets in the treatment of colitis gravis

作　　者：赵志军[1] 尹学永[1] 李宝纯[1] 张英[1] Zhao Zhijun;Yin Xueyong;Li Baochun;Zhang Ying(Department of Gastroenterology,the Second Hospital of Qinhuangdao,Qinhuangdao,Hebei 066600,China)

机构地区：[1]秦皇岛市第二医院消化内科,河北省秦皇岛066600

出　　处：《中国基层医药》2018年第15期1922-1924,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 分析美沙拉嗪联合酪酸梭菌活菌片治疗溃疡性结肠炎的临床疗效及安全性.方法 选取秦皇岛市第二医院2016年1～12月溃疡性结肠炎患者120例为研究对象,根据治疗方法不同分为观察组和对照组各60例.对照组采用美沙拉嗪治疗,观察组采用美沙拉嗪联合酪酸梭菌活菌治疗,两组疗程均为2个月.观察两组治疗前后细胞因子、C反应蛋白水平的变化,比较两组治疗效果、不良反应.结果 观察组总有效率明显高于对照组（91.66%比78.33%）,两组差异有统计学意义（χ2＝4.183,P＝0.041）.治疗后,观察组白细胞介素10（IL-10）[（110.05 ±2.61）pg/L]明显高于对照组[（98.35 ±2.42）pg/L]（t＝25.462,P＜0.05）,IL-18[（97.74 ±2.82）pg/L]明显低于对照组[（120.86 ±3.21）pg/L]（t＝41.914,P＜0.05）,C反应蛋白[（8.02 ±1.97）mg/L]低于对照组[（6.33 ±3.82）mg/L]（t＝14.976,P＜0.05）;观察组不良反应发生率明显低于对照组（5.00%比25.00%）（χ2＝9.412,P＝0.002）.结论 美沙拉嗪联合酪酸梭菌活菌治疗溃疡性结肠炎有明显的疗效,能有效改善患者的细胞因子、C-反应蛋白水平,且安全性较高.Objective To investigate the clinical efficacy and safety of mesalazine combined with Clostridium butyricum tablets in the treatment of colitis gravis.Methods From January 2016 to December 2016, a total of 120 patients with colitis gravis in the Second Hospital of Qinhuangdao were selected in the research .According to different treatment methods,the patients were divided into observation group and control group ,with 60 cases in each group.The control group was given mesalazine , and the observation group was given mesalazine combined with Clostridium butyricum tablets.All the patients were treated for 2 months.The changes of cytokine levels and C -reactive protein were observed.The therapeutic effects and adverse drug reactions were compared between the two groups . Results The total effective rate of the observation group was significantly higher than that in the control group （91.66%vs.78.33%）,and there was statistically significant difference between the two groups （ χ2＝4.183,P＝0.041）.The level of IL-10 in the observation group was significantly higher than that in the control group [（110.05 ± 2.61）pg/L vs.（98.35 ±2.42）pg/L,t＝25.462,P＜0.05].The IL-18 level in the observation group was significantly lower than that in the control group [（97.74 ±2.82） pg/L vs.（120.86 ±3.21） pg/L,t＝41.914,P＜0.05].The level of C-reactive protein in the observation group was lower than that in the control group [（8.02 ±1.97） mg/L vs.（6.33 ±3.82）mg/L,t＝14.976,P＜0.05].The incidence rate of adverse reactions of the observation group was significantly lower than that of the control group （ 5.00% vs.25.00%, χ2＝9.412, P ＝0.002 ）.Conclusion Mesalazine combined with Clostridium butyricum tablets in the treatment of colitis gravis has obvious curative effect , and can effectively improve the levels of cytokines and C -reactive protein and with high safety.

关 键 词：结肠炎 溃疡性 美沙拉嗪 酪酸梭菌活菌片 

分 类 号：R574.62[医药卫生—消化系统]